Pharmaceutical - Eli Lilly

Filter

Current filters:

Eli Lilly

Popular Filters

1 to 25 of 199 results

UK NICE wants more info on type 2 diabetes drug Jardiance

UK NICE wants more info on type 2 diabetes drug Jardiance

28-08-2014

In a new draft guidance issued today, the UK drugs watchdog the National Institute for Health and Care…

Boehringer IngelheimDiabetesEli LillyJardiancePharmaceuticalPricingRegulationUK

Lilly’s ixekizumab shows superiority over etanercept and placebo in Ph III

Lilly’s ixekizumab shows superiority over etanercept and placebo in Ph III

21-08-2014

US pharma major Eli Lilly’s investigational medicine ixekizumab was superior to etanercept and placebo…

Eli LillyInflammatory diseasesixekizumabPharmaceuticalRegulationResearch

Lilly and Boehringer closing in on diabetes market lead with Jardiance approval

Lilly and Boehringer closing in on diabetes market lead with Jardiance approval

07-08-2014

With the recent approval of Jardiance (empagliflozin) in the USA, Eli Lilly and its partner, German family-owned…

Boehringer IngelheimDiabetesEli LillyEli Lilly and CompanyJanuviaJardianceMarkets & MarketingMerck & CoPharmaceuticalTradjenta

US FDA approves Jardiance for adults with type 2 diabetes

US FDA approves Jardiance for adults with type 2 diabetes

02-08-2014

The US Food and Drug Administration on Friday approved Jardiance (empagliflozin) tablets as an adjunct…

Boehringer IngelheimDiabetesEli LillyEuropeGermanyJardiancePharmaceuticalRegulationUSA

Eli Lilly to establish production of insulin in Russia

Eli Lilly to establish production of insulin in Russia

29-07-2014

US pharma major Eli Lilly has reached an agreement with one of Russia’s leading drugmakers, R-Pharm,…

DiabetesEli LillyHumulin RInsulinPharmaceuticalProductionR-PharmRussia

Global insulin market set to reach $32.24 billion in 2019

Global insulin market set to reach $32.24 billion in 2019

28-07-2014

The global insulin market was valued at $19.99 billion in 2012 and is expected to expand at a compound…

AfrezzaChinaDiabetesEli LillyGlobalInsulinLY2605541MannKindMarkets & MarketingMerck & CoMK-1293NN1218Novo NordiskPharmaceutical

Eli Lilly 2nd-qtr sales takes hit from generics; net income falls 39%

24-07-2014

US pharma major Eli Lilly reported second quarter 2014 revenues fell 17% to $4.935 billion, reflecting…

Eli LillyFinancialPharmaceutical

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

23-07-2014

The National Institute for Health and Care Excellence (NICE), the UK’s health care guidance body, has…

Acute coronary syndromesCardio-vascularEfientEli LillyPharmaceuticalprasugrelRegulationUK

Seven pharma companies offer up compounds to UK researchers

Seven pharma companies offer up compounds to UK researchers

22-07-2014

UK researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds…

AstraZenecaEli LillyGlaxoSmithKlineJanssenMedical Research CouncilPfizerPharmaceuticalResearchTakeda PharmaceuticalUCBUK

China’s Yabao Pharma partners with Eli Lilly to develop diabetes candidate

China’s Yabao Pharma partners with Eli Lilly to develop diabetes candidate

08-07-2014

Chinese drugmaker Yabao Pharmaceutical has entered a strategic partnership with US pharma major Eli Lilly…

ChinaDiabetesEli LillyLicensingPharmaceuticalYabao Pharmaceutical

UK’s NICE draft guidance recommends Lilly’s Efient

UK’s NICE draft guidance recommends Lilly’s Efient

20-06-2014

UK health care watchdog the National Institute for Health and Care Excellence (NICE) has today published…

Cardio-vascularEfientEli LillyPharmaceuticalPricingRegulationUK

Boehringer and Lilly re-file empagliflozin NDA with FDA

Boehringer and Lilly re-file empagliflozin NDA with FDA

19-06-2014

The US subsidiary of German family-owned drugmaker Boehringer Ingelheim and pharma major Eli Lilly have…

Boehringer IngelheimDiabetesEli LillyempagliflozinPharmaceuticalRegulationUSA

Lilly’s Cyramza disappoints in Ph III liver cancer trial

Lilly’s Cyramza disappoints in Ph III liver cancer trial

12-06-2014

US drug major Eli Lilly (NYSE: LLY) says the Phase III REACH trial of Cyramza (ramucirumab) in patients…

ChemistryCyramzaEli LillyHealth Medical PharmaLillyMajorOncologyOrganic chemistryPharmaceuticalResearch

Boehringer and Lilly’s diabetes drug Jardiance gains EU approval

23-05-2014

German family-owned pharma major Boehringer Ingelheim and US partner Eli Lilly have received Marketing…

Boehringer IngelheimDiabetesEli LillyempagliflozinEuropeJardiancePharmaceuticalRegulation

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

13-05-2014

US pharma major Eli Lilly has released positive top-line results of three completed Phase III clinical…

DiabetesEli LillyLantuspeglisproPharmaceuticalResearchSanofi

Lilly to appeal $450 million fine in Brazil labor case

Lilly to appeal $450 million fine in Brazil labor case

10-05-2014

US drug major Eli Lilly revealed on Friday that the 2nd Circuit of the Labor Court of Paulinia in the…

BrazilEli LillyLegalPharmaceuticalProduction

Eli Lilly 1st-qtr 2014 net income plunges, sales down, hit by generic competition

24-04-2014

US pharma major Eli Lilly posted first-quarter 2014 financial results, with revenue declined 16 % to…

Eli LillyFinancialPharmaceutical

1 to 25 of 199 results

Back to top